News
11-07-2011, 10:00 PM
Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.
More... (http://www.news-medical.net/news/20111107/New-data-from-Pfizers-hematology-portfolio-to-be-presented-at-53rd-ASH-annual-meeting.aspx)
More... (http://www.news-medical.net/news/20111107/New-data-from-Pfizers-hematology-portfolio-to-be-presented-at-53rd-ASH-annual-meeting.aspx)